ESMO 2021: MONALEESA-2 Update Confirms Overall Survival Benefit With Addition of Ribociclib to Letrozole in Advanced Breast Cancer
This is the first trial with survival benefits beyond 5 years in advanced breast cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.